3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Motor Activity
32
Breast Neoplasms
21
Neoplasms
17
Prostatic Neoplasms
11
Obesity
8
Colorectal Neoplasms
6
Sarcopenia
5
Pancreatic Neoplasms
5
Lung Neoplasms
5
Polycystic Ovary Syndrome
4
Head and Neck Neoplasms
4
Signs and Symptoms
3
Multiple Myeloma
3
Lymphedema
3
Inflammation
3
Fatigue
3
Diabetes Mellitus, Type 2
3
Colonic Neoplasms
3
Brain Neoplasms
3
Uterine Cervical Neoplasms
2
Pharyngeal Neoplasms
2
Overweight
2
Osteoporosis, Postmenopausal
2
Osteoporosis
2
Lymphoma
2
Leukemia, Myeloid, Acute
2
Leukemia
2
Laryngeal Neoplasms
2
Insulin Resistance
2
Endometrial Neoplasms
2
Interventions
fludarabine phosphate
21
Cyclophosphamide
20
Peripheral Blood Stem Cell Transplantation
19
Busulfan
16
Tacrolimus
14
Whole-Body Irradiation
12
Methotrexate
12
Mycophenolic Acid
11
Cyclosporine
11
Antilymphocyte Serum
10
fludarabine
6
Filgrastim
6
peginterferon alfa-2a
5
ruxolitinib
4
Radiotherapy
4
Methylprednisolone
4
Melphalan
4
Flow Cytometry
4
Etoposide
4
Decitabine
4
Aspirin
4
Stem Cell Transplantation
3
Injections
3
Cytogenetic Analysis
3
Cytarabine
3
Biopsy
3
Azacitidine
3
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
3
merphos
2
aldesleukin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Thrombocythemia, Essential
×
Resistance Training
×
Clear all
NCT07518940
2026-04-09
ENERGIA
University of Turin, Italy
Phase NA
Not yet recruiting
25 enrolled